CJC/Ipamorelin + MK-677 Stack Protocol
The CJC-1295/Ipamorelin + MK-677 stack combines injectable GHRH/GHRP peptides with an oral GH secretagogue for the most comprehensive growth hormone axis optimization available. CJC-1295 (Mod GRF 1-29) amplifies GH pulse amplitude via the GHRH receptor, Ipamorelin initiates clean GH pulses via ghrelin receptor without elevating cortisol or prolactin, and MK-677 (Ibutamoren) provides sustained 24-hour GH elevation and robust IGF-1 increase through oral ghrelin mimetic activity with a ~24-hour half-life. This triple approach optimizes both pulsatile and tonic GH secretion, producing superior IGF-1 elevation and body composition improvements. Protocol covers combined SubQ + oral dosing, insulin sensitivity monitoring, timing optimization, and advanced cycling strategies.
Protocol Overview
- Compounds
- CJC-1295 no DAC + Ipamorelin + MK-677 (Ibutamoren)
- Category
- Growth Hormone Optimization (Advanced)
- Mechanism
- GHRH analog + selective GHRP + oral ghrelin mimetic; triple-axis GH optimization via pulsatile + tonic secretion
- Route
- SubQ (CJC/Ipa) + Oral (MK-677)
- Frequency
- CJC/Ipa: 2x daily SubQ | MK-677: 1x daily oral (PM)
- Cycle Length
- 12-16 weeks on, 4-8 weeks off
Dosing Protocol
| Protocol | CJC-1295 | Ipamorelin | MK-677 | Duration |
|---|---|---|---|---|
| Standard | 100 mcg 2x/day | 100 mcg 2x/day | 12.5 mg at night | 12-16 weeks |
| Advanced | 100 mcg 2x/day | 100 mcg 2x/day | 25 mg at night | 12-16 weeks |
| Alternating | 100 mcg 2x/day | 100 mcg 2x/day | 25 mg (non-inj. days) | 12-16 weeks |
Key principle: CJC/Ipa should be taken fasted (AM + pre-bed). MK-677 at bedtime leverages the natural nocturnal GH surge. The "alternating" approach reduces insulin resistance risk by not stacking all three GH stimuli daily. Monitor glucose closely with the advanced protocol.
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Increased appetite (MK-677 ghrelin activity)
- Water retention / bloating (weeks 1-3)
- Numbness/tingling in extremities
- Vivid dreams / deeper sleep
- Mild lethargy if glucose elevated
Critical Precautions
- Monitor fasting glucose and HbA1c closely
- MK-677 can reduce insulin sensitivity significantly
- Contraindicated with diabetes or pre-diabetes
- Avoid with active cancer (GH/IGF-1 proliferative)
- Check thyroid function (GH can increase T4-to-T3 conversion)
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| GH / IGF-1 | IGF-1, IGFBP-3 | Baseline, Week 6, Week 12 |
| Metabolic | Fasting glucose, insulin, HbA1c, HOMA-IR | Baseline, Week 4, Week 8, Week 12 |
| Thyroid | TSH, fT3, fT4 | Baseline, Week 8 |
| Liver/Kidney | CMP, ALT, AST | Baseline, Week 12 |
| Body Composition | DEXA scan | Baseline, Week 12 |
Related Tools & Resources
There is no validated human dose for this compound; the following is a commonly cited research convention, not a validated protocol. The standard protocol uses 100mcg CJC-1295 + 100mcg Ipamorelin subcutaneously 2x daily (AM fasted + pre-bed), combined with MK-677 12.5-25mg orally at bedtime. Some protocols use MK-677 only on non-injection days to reduce insulin resistance risk from continuous GH elevation.
Sustained GH elevation from MK-677 combined with pulsatile GH from CJC/Ipa can reduce insulin sensitivity over time. Monitor fasting glucose and HbA1c. Strategies to mitigate this include: using MK-677 only on non-injection days, starting MK-677 at 12.5mg, adding berberine or metformin, and incorporating regular fasted-state exercise.
CJC-1295/Ipamorelin provides acute pulsatile GH release mimicking natural physiology, while MK-677 provides sustained baseline GH elevation and IGF-1 increase over 24 hours through oral ghrelin mimetic activity. Combined, they optimize both the pulsatile and tonic components of GH secretion, producing superior IGF-1 elevation and body composition improvements compared to either approach alone.
There is no validated human dose for this compound; the following is a commonly cited research convention, not a validated protocol. The standard protocol uses 100mcg CJC-1295 + 100mcg Ipamorelin subcutaneously 2x daily (AM fasted + pre-bed), combined with MK-677 12.5-25mg orally at bedtime. Some protocols use MK-677 only on non-injection days to reduce insulin resistance risk from continuous GH elevation.
Sustained GH elevation from MK-677 combined with pulsatile GH from CJC/Ipa can reduce insulin sensitivity over time. Monitor fasting glucose and HbA1c. Strategies to mitigate this include: using MK-677 only on non-injection days, starting MK-677 at 12.5mg, adding berberine or metformin, and incorporating regular fasted-state exercise.